{
  "source": "PA-Notification-Xolremdi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1454-1\nProgram Prior Authorization/Notification\nMedication Xolremdi™ (mavorixafor)\nP&T Approval Date 8/2024\nEffective Date 10/15/2024\n1. Background:\nXolremdi™ (mavorixafor) is a CXC chemokine receptor 4 antagonist indicated in patients 12\nyears of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and\nmyelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Xolremdi will be approved based on the following criterion:\na. Diagnosis of WHIM (warts, hypogammaglobulinemia, infections and\nmyelokathexis) syndrome\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Xolremdi will be approved based on the following criterion:\na. Documentation of positive clinical response to Xolremdi therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Medical Necessity and Supply limits may be in place.\n4. References:\n1. Xolremdi [package insert]. Boston, MA: X4 Pharmaceuticals, Inc.; April 2024.\n© 2024 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification - Xolremdi™ (mavorixafor)\nChange Control\n8/2024 New program.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}